Additional Relevant Details Concert Pharmaceuticals along with Avanir Pharmaceuticals launched two phase 3 studies in November 2015 for the study of AVP-786 on patients with Alzheimers.  The primary endpoint studies the efficacy of the drug on the treatment of agitation.  The studies are projected to complete mid 2018.